Perivascular treatment with azathioprine reduces neointimal hyperplasia in experimental vein grafts

Heart Surgery Forum

Volumn 9, Issue 1, 2006, Pages 17-19

  Schachner, Thomas ^a   Heiss, Simone ^a   Zipponi, Daniel ^a   Tzankov, Alexander ^a   Bernecker, Oliver ^a   Kroell, Arthur ^a   Laufer, Günther ^a   Bonatti, Johannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; COMMON CAROTID ARTERY; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL SURGERY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFERIOR CAVA VEIN; ISOGRAFT; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; VEIN GRAFT; VEIN GRAFT DISEASE; VEIN INTIMA PROLIFERATION; VEIN OCCLUSION; ANIMAL; C57BL MOUSE; DRUG EFFECT; HYPERPLASIA; INTIMA; NICK END LABELING; PATHOLOGY; TRANSPLANTATION; VASCULAR SURGERY;

ANIMALS; APOPTOSIS; AZATHIOPRINE; CAROTID ARTERY, COMMON; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; TUNICA INTIMA; VASCULAR SURGICAL PROCEDURES; VENA CAVA, INFERIOR;

EID: 33746862906     PISSN: 10983511     EISSN: None     Source Type: Journal    
DOI: 10.1532/HSF98.20051168     Document Type: Article

References (10)

1. Arruda JA, Costa MA, Brito FS, et al. 2003. Effect of systemic immuno-suppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol 91:1363-5.
2. Belgi G, Friedmann PS. 2002. Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea. Z Hautkr 77:624-32.
3. Maltzman JS, Koretzky GA. 2003. Azathioprine: old drug, new actions. J Clin Invest 111:1122-24.
4. Mingoli A, Edwards JD, Feldhaus RJ, et al. 1996. Fresh vein allograft survival in dogs after cyclosporine treatment. J Surg Res 62:95-102.
5. Schachner T, Oberhuber A, Zou Y, et al. 2005. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardio Thorac Surg 27:302-6.
6. Schachner T, Zou Y, Oberhuber A, et al. 2004. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 25:585-90.
7. Schachner T, Zou Y, Oberhuber A, et al. 2004. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 77:1580-85.
8. Schwab M, Herrlinger K, Schaeffeler E, Stange EF. 2003. Therapie chronisch entzündlicher darmerkrankungen mit azathioprin, 6-Mercaptopurin und 6-Thioguanin [in German]. Dtsch Med Wochenschr 128:378-85.
9. Tiede I, Fritz G, Strand S, et al. 2003. CD28-dependent Racl activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133-45.
10. Zou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q. 1998. Mouse model of venous bypass graft disease. Am J Pathol 153:1301-10.